TIMSER S.A.P.I. de C.V.
TIMSER S.A.P.I. de C.V. is a biomedical company in Mexico developing accessible and non-invasive blood-based screening solutions for early detection of cervical cancer and its precursor lesions. The company leverages more than a decade of research to advance clinically validated molecular diagnostics using protein biomarkers identified through proteomics and molecular biology approaches. These technologies address barriers to traditional screening and are backed by extensive national and international patent coverage and clinical trial validation involving hundreds of participants.
TIMSER S.A.P.I. de C.V.
Avenida Adolfo López Mateos, Periférico Sur 4349, Local 6, Jardines en la Montaña, Tlalpan, 14210, Ciudad de México, Mexico
TIMSER S.A.P.I. de C.V. is currently seeking investment
TIMSER S.A.P.I. de C.V. is seeking a series-a investment in the range of 5m-20m
Patents
Methods of diagnosing cervical cancer based on altered polypeptide expression and treatment thereof
2025-10-07 • US-12433933-B2
View DetailsPharmaceutical composition containing pentacyclic triterpenoids
2024-03-19 • US-11931372-B2
View DetailsMethods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase
2021-11-02 • US-11160844-B2
View DetailsMethods of diagnosing and treating cervical cancer or a high-grade cervical lesion based on expression of ankyrin-3
2021-11-02 • US-11160845-B2
View Details
Methods of diagnosing cervical cancer based on altered polypeptide expression and treatment thereof
2025-10-07 • US-12433933-B2
View DetailsPharmaceutical composition containing pentacyclic triterpenoids
2024-03-19 • US-11931372-B2
View DetailsMethods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase
2021-11-02 • US-11160844-B2
View DetailsMethods of diagnosing and treating cervical cancer or a high-grade cervical lesion based on expression of ankyrin-3
2021-11-02 • US-11160845-B2
View DetailsWhat We Do
A clinically validated diagnostic platform detecting a panel of circulating protein biomarkers from blood samples to identify risk of cervical precancerous lesions and cancer as an accessible, non-invasive alternative to cytology and HPV-based tests.
A clinically validated diagnostic platform detecting a panel of circulating protein biomarkers from blood samples to identify risk of cervical precancerous lesions and cancer as an accessible, non-invasive alternative to cytology and HPV-based tests.
Application Area
Infectious Diseases
Diagnostics
Digital Health Technologies
Services
Key People
Founder and President
CEO, General Director (Timser Group)
Research Team Lead
Gynecology-Oncology Specialist
General Practitioner
Gynecology and Obstetrics
Founder and President
CEO, General Director (Timser Group)
Research Team Lead
Gynecology-Oncology Specialist
General Practitioner
Gynecology and Obstetrics
News & Updates
Received national recognition for biomedical technology innovation.
Identified as a leading FemTech startup with global impact.
Mentioned as an example of scientific advancement and social contribution in women’s health technology.
Awarded at the global forum for contributions to improving health outcomes for women.
Coverage in Expansion magazine highlighting Mexico-based innovation in laboratory-based cervical cancer screening.
Article in Líderes Mexicanos discussing global and local impact and the importance of timely cervical cancer diagnosis.
Received national recognition for biomedical technology innovation.
Identified as a leading FemTech startup with global impact.
Mentioned as an example of scientific advancement and social contribution in women’s health technology.
Awarded at the global forum for contributions to improving health outcomes for women.
Coverage in Expansion magazine highlighting Mexico-based innovation in laboratory-based cervical cancer screening.
Article in Líderes Mexicanos discussing global and local impact and the importance of timely cervical cancer diagnosis.